Oryzon Genomics Future Growth
Future criteria checks 3/6
Oryzon Genomics is forecast to grow earnings and revenue by 65.9% and 65.8% per annum respectively while EPS is expected to grow by 64.5% per annum.
Key information
65.9%
Earnings growth rate
64.5%
EPS growth rate
Biotechs earnings growth | 31.0% |
Revenue growth rate | 65.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch
Jun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Apr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts
Jul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
May 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
Feb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns
Jan 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 28 | 5 | N/A | N/A | 2 |
12/31/2025 | N/A | -1 | N/A | N/A | 2 |
12/31/2024 | N/A | -6 | N/A | N/A | 3 |
12/31/2023 | N/A | -4 | N/A | N/A | N/A |
9/30/2023 | 17 | -4 | N/A | N/A | N/A |
6/30/2023 | 17 | -4 | -21 | -3 | N/A |
3/31/2023 | 17 | -5 | N/A | N/A | N/A |
12/31/2022 | 17 | -5 | -17 | -2 | N/A |
9/30/2022 | 10 | -3 | N/A | N/A | N/A |
6/30/2022 | 14 | -5 | -15 | -3 | N/A |
3/31/2022 | 12 | -5 | N/A | N/A | N/A |
12/31/2021 | 12 | -5 | -18 | -4 | N/A |
9/30/2021 | 11 | -4 | N/A | N/A | N/A |
6/30/2021 | 10 | -4 | -17 | -4 | N/A |
3/31/2021 | 7 | -5 | N/A | N/A | N/A |
12/31/2020 | 12 | -4 | -17 | -6 | N/A |
9/30/2020 | 12 | -4 | N/A | N/A | N/A |
6/30/2020 | 13 | -4 | -16 | -4 | N/A |
3/31/2020 | 13 | -4 | N/A | N/A | N/A |
12/31/2019 | 12 | -4 | -15 | -4 | N/A |
9/30/2019 | 10 | -4 | N/A | N/A | N/A |
6/30/2019 | 9 | -4 | -11 | -3 | N/A |
3/31/2019 | 8 | -2 | N/A | N/A | N/A |
12/31/2018 | 8 | -1 | -9 | -1 | N/A |
9/30/2018 | 7 | -2 | N/A | N/A | N/A |
6/30/2018 | 6 | -2 | -11 | -5 | N/A |
3/31/2018 | 6 | -6 | N/A | N/A | N/A |
12/31/2017 | 5 | -6 | -11 | -6 | N/A |
9/30/2017 | 6 | -6 | N/A | N/A | N/A |
6/30/2017 | 6 | -6 | N/A | -4 | N/A |
3/31/2017 | 5 | -6 | N/A | N/A | N/A |
12/31/2016 | 5 | -6 | N/A | -5 | N/A |
9/30/2016 | 6 | -5 | N/A | N/A | N/A |
6/30/2016 | 6 | -4 | N/A | -1 | N/A |
3/31/2016 | 8 | -1 | N/A | N/A | N/A |
12/31/2015 | 8 | -1 | N/A | 1 | N/A |
9/30/2015 | 8 | -1 | N/A | N/A | N/A |
6/30/2015 | 7 | -1 | N/A | N/A | N/A |
3/31/2015 | 11 | 2 | N/A | N/A | N/A |
12/31/2014 | 19 | 8 | N/A | 15 | N/A |
12/31/2013 | 3 | -3 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: ORY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ORY is expected to become profitable in the next 3 years.
Revenue vs Market: ORY is forecast to have no revenue next year.
High Growth Revenue: ORY is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORY's Return on Equity is forecast to be high in 3 years time